CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
合成更智能的 CAR-T 细胞：T 细胞免疫疗法的先进工程化改造
英文原题：Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies.
查看英文原题
Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫系统包含一系列特化细胞，通过响应病原体信号来维持我们的健康。对免疫细胞行为机制的研究促成了强效免疫疗法的发展，包括嵌合抗原受体（CAR）T细胞。尽管CAR-T 细胞在治疗血液癌症方面已显示出疗效，但有关其安全性和效力的问题阻碍了免疫疗法在更广泛疾病谱中的应用。将合成生物学进展整合到免疫治疗中的努力已带来若干进步，有望扩大可治疗疾病的范围、精细调控所需的免疫反应，并提高治疗细胞的效力。在此，我们审视当前旨在改进现有技术的合成生物学进展，并讨论下一代工程化免疫细胞疗法的前景。
展开英文摘要原文
The immune system includes an array of specialized cells that keep us healthy by responding to pathogenic cues. Investigations into the mechanisms behind immune cell behavior have led to the development of powerful immunotherapies, including chimeric-antigen receptor (CAR) T cells.
Although CAR T cells have demonstrated efficacy in treating blood cancers, issues regarding their safety and potency have hindered the use of immunotherapies in a wider spectrum of diseases. Efforts to integrate developments in synthetic biology into immunotherapy have led to several advancements with the potential to expand the range of treatable diseases, fine-tune the desired immune response, and improve therapeutic cell potency.
Here, we examine current synthetic biology advances that aim to improve on existing technologies and discuss the promise of the next generation of engineered immune cell therapies.
论文信息
- 作者
- Zhu I、Piraner DI、Roybal KT
- 单位
- Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California.United States
- 期刊
- Cancer immunology research2023 Aug 3
- 原文标识
- PubMed 37429007 · DOI 10.1158/2326-6066.CIR-22-0962
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →